Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel-Reference-Cited by-同舟云学术

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel

Published:2017-12 Issue: Volume:120 Page:52-59
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Müller Martin C.,Cervantes Francisco,Hjorth-Hansen Henrik,Janssen Jeroen J.W.M.,Milojkovic Dragana,Rea Delphine,Rosti Gianantonio

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference65 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

2. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study;Baccarani;Int. J. Hematol.,2014

3. Long-term follow-up of ponatinib efficacy and safety in patients (pts) with the T315I mutation in the phase 1 and phase 2 (PACE) trials [abstract];Baccarani;Haematologica,2015

4. Bosulif [summary of product characteristics]. Pfizer Limited, Sandwich, United Kingdom, 2017, March 30, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002373/WC500141721.pdf.

5. Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation;Cornelison;Clin. Lymphoma Myeloma Leuk.,2011

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08

2. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

3. A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia;Pharmaceutics;2024-03-11

4. Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights;Frontiers in Cardiovascular Medicine;2023-09-14

5. Ponatinib: An update on its drug targets, therapeutic potential and safety;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09